ArticleMethods in molecular biology (Clifton, N.J.)2026
Determination of the Inhibitory Properties of Compounds Toward Immune Checkpoint Complex Formation Using ELISA.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ELISA is one of the most widely used methods in immunology, molecular biology, and medical diagnostics. It enables the detection and quantification of specific proteins, antibodies, antigens, or hormones in biological samples such as blood serum, urine, or cerebrospinal fluid. ELISA is highly sensitive and specific, which makes it extremely useful in various fields of scientific research and clinical diagnosis. In recent years, this method has gained importance in the context of research on immune checkpoint inhibitors. Immune checkpoint inhibitors, such as antibodies, peptides, or small-molecule compounds that block receptor/ligand complex formation, have become modern therapeutic tools in immuno-oncology. Therefore, more and more research is being conducted in this field. ELISA is a relatively cheap and rapid method that can be effectively used to verify the initial inhibitory potential of compounds before more expensive and much more sophisticated cell-based assays are performed. In this protocol, we described how the inhibitory properties of compounds toward immune checkpoint complex formation can be investigated using ELISA and provided a detailed procedure that was used to evaluate the inhibitory properties of peptides toward the BTLA/HVEM complex formation.
Indexed as
Identifiers
41028256What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.